Prognostic value of pretreatment contrast-enhanced computed tomography in esophageal neuroendocrine carcinoma: A multi-center follow-up study

doi:10.3748/wjg.v26.i31.4680

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 26, Issue 31

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5155)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

244

WORD

116

HTML

2043

Figures (1-3)

257

Tables (1-4)

204

Sum=2864

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

676

Download

1615

Sum=2291

Aug 21, 2020 (publication date) through Jul 26, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Aug 21, 2020; 26(31): 4680-4693
Published online Aug 21, 2020. doi: 10.3748/wjg.v26.i31.4680

Table 3 Multivariate analysis of clinical factors and computed tomography characteristics of the patients

Variable	B	Wald	P value	HR	95%CI
PFS
Adjuvant chemotherapy (Performed vs none)	1.861	15.075	< 0.001	6.432	2.514-16.485
OS
N stage (Absent vs present)	-0.853	5.079	0.024	0.426	0.203-0.895
Adjuvant chemotherapy (Performed vs none)	1.351	7.658	0.006	3.862	1.483-10.058
Degree of enhancement (Mild vs moderate/marked)	0.774/-0.212	6.581	0.037	2.169/0.809	0.827-5.689/0.285-2.296

OS: Overall survival; PFS: Progression-free survival; HR: Hazard ratio.

Citation: Zhou Y, Hou P, Zha KJ, Wang F, Zhou K, He W, Gao JB. Prognostic value of pretreatment contrast-enhanced computed tomography in esophageal neuroendocrine carcinoma: A multi-center follow-up study. World J Gastroenterol 2020; 26(31): 4680-4693
URL: https://www.wjgnet.com/1007-9327/full/v26/i31/4680.htm
DOI: https://dx.doi.org/10.3748/wjg.v26.i31.4680